DIAGNOS Celebrates the Launch of Labtician's New Screening Service for Diabetic Retinopathy in Ontario and Renews Its Distribution Agreement

BROSSARD, Quebec, May 21, 2024 (GLOBE NEWSWIRE) -- DIAGNOS Inc. ("DIAGNOS" or the "Corporation") (TSX Venture: ADK) (OTCQB: DGNOF), a pioneer in early detection of critical health issues through its

GlobeNewswireMay 21 09:00 ET

DIAGNOS Inc. Advances AI Health Tech With Funding

TipRanksMay 9 16:50 ET

Diagnos Inc Unveils AI Breakthroughs in Eye Health

TipRanksMay 6 09:37 ET

DIAGNOS to Present Cutting-Edge AI Solutions for Retinal Health at ARVO 2024

BROSSARD, Quebec, May 06, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or "the Company") (TSX Venture: ADK) (OTCQB: DGNOF), a provider of healthcare services in early detection of certain critic

GlobeNewswireMay 6 09:00 ET

Diagnos Inc. Advances AI Healthcare Modules

TipRanksApr 16 11:37 ET

DIAGNOS to Expedite Application for Medical Device License to Health Canada and US FDA Related to Its 4 New Analysis Modules, and Is Planning ISO 27001 Certification

BROSSARD, Quebec, April 16, 2024 (GLOBE NEWSWIRE) -- Diagnos Inc. ("DIAGNOS" or "the Company") (TSX Venture: ADK) (OTCQB: DGNOF), a provider of healthcare services in early detection of certain crit

GlobeNewswireApr 16 11:08 ET